Biotech AssistantIndependent biopharma research
BIOTECH ASSISTANT / FIELD NOTES

Umoja schedules first UB-VV400 clinical presentation and additional in vivo CAR-T updates at ASH

Company / institutional announcement · Umoja Biopharma / GlobeNewswire

Source published: · Event / reporting date: 2026-11-04

Site published: 2026-11-05 · Updated: 2026-11-05

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗
Findings and limitationsIndustry implicationsRelated developments

What changed

Umoja announced four accepted ASH presentations, including clinical data from investigator-initiated studies of CD22-directed UB-VV400 in B-cell malignancies and UB-VV410 in lupus. Separate trial-in-progress posters concern UB-VV400 and BCMA/GPRC5D-directed UB-VV500. The announcement schedules December presentations rather than providing numerical response or safety results from those studies.

Why it may matter

Analysis: Upcoming human data could clarify delivery and safety questions; conference acceptance alone does not demonstrate efficacy or comparative advantage.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

In Vivo Cell Engineering & Gene Editing

Related updates

Intellia Therapeutics

Intellia reports completed MAGNITUDE-2 enrollment and advances launch preparations

Intellia's third-quarter update reports completed enrollment in the Phase 3 MAGNITUDE-2 trial of nexiguran ziclumeran for hereditary ATTR amyloidosis with polyneuropathy, exceeding the target of 60 randomized patients. The company also described commercial preparations for lonvoguran ziclumeran in hereditary angioedema, ahead of its March 10, 2027 FDA target action date. Approval remains pending.

In Vivo Cell Engineering & Gene EditingAsk AI ↗
Precision BioSciences / Business Wire

Safety board supports further PBGENE-DMD dosing after first patient's eight-week review

Precision BioSciences said an independent safety board endorsed additional dosing in the Phase 1/2 FUNCTION-DMD study after reviewing the first PBGENE-DMD recipient's eight-week observation period. No serious adverse events or adverse events of special interest were reported in that patient. The AAV-delivered gene-editing program remains investigational; this single-patient review does not establish efficacy or broader safety.

In Vivo Cell Engineering & Gene EditingAsk AI ↗
Precision BioSciences / Business Wire

Precision reports new ELIMINATE-B gene-editing data and plans Phase 2

Precision BioSciences reported updated PBGENE-HBV Phase 1 data covering 25 patients and 59 administrations. The company described pgRNA loss and liver-biopsy evidence of cccDNA reduction at the expected go-forward dose of 0.4 mg/kg, with no dose-limiting toxicities reported. It plans Phase 2 evaluation, including assessment after nucleos(t)ide analog withdrawal; viral cure has not been established.

In Vivo Cell Engineering & Gene EditingAsk AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗
AI assistant ↗